{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:29:18Z","timestamp":1772166558980,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AT006899"],"award-info":[{"award-number":["R01AT006899"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DA041359"],"award-info":[{"award-number":["R01DA041359"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30 DA013429"],"award-info":[{"award-number":["P30 DA013429"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Res Notes"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Selective kappa opioid receptor (KOR) agonists were shown to produce a dose-dependent depression of brain-stimulation reward (BSR) in the rat intracranial self-stimulation (ICSS) tests. However, limited studies using mice produced less conclusive results. Here the effects of U50,488H were re-examined on BSR in mice with a larger cohort of animals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Forty C57BL\/6J male mice were implanted with the electrodes in medial forebrain bundle. About a week after surgery, mice were subject to ICSS training. Only eighteen passed the two-phase procedures, at which point they readily spun the wheels to obtain reinforcing effect of BSR, and were used for the ICSS tests. Compared with saline (s.c.), U50,488H (2\u00a0mg\/kg, s.c.) did not have effects on the BSR thresholds within 1\u00a0h post-treatment, while it decreased the maximum wheel-spinning rates in a time-dependent manner. In contrast, cocaine (5\u00a0mg\/kg, s.c.) decreased the BSR thresholds time-dependently without affecting the maximum wheel-spinning rates in the same cohort of mice, demonstrating the validity of our mouse ICSS models. For comparison, U50,488H (2\u00a0mg\/kg, s.c.) induced significant conditioned place aversion (CPA) in a different cohort of mice without surgeries. Thus, ICSS may not be an appropriate test for KOR agonist-induced aversion in mice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13104-020-05227-7","type":"journal-article","created":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T13:03:12Z","timestamp":1597410192000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["The kappa opioid receptor agonist U50,488H did not affect brain-stimulation reward while it elicited conditioned place aversion in mice"],"prefix":"10.1186","volume":"13","author":[{"given":"Peng","family":"Huang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor A.","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John W.","family":"Muschamp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lee-Yuan","family":"Liu-Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,14]]},"reference":[{"key":"5227_CR1","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1126\/science.3016896","volume":"233","author":"A Pfeiffer","year":"1986","unstructured":"Pfeiffer A, Brantl V, Herz A, Emrich HM. Psychotomimesis mediated by kappa opiate receptors. Science. 1986;233:774\u20136.","journal-title":"Science"},{"key":"5227_CR2","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/j.biopsych.2012.06.012","volume":"72","author":"M Ranganathan","year":"2012","unstructured":"Ranganathan M, Schnakenberg A, Skosnik PD, Cohen BM, Pittman B, Sewell RA, D\u2019Souza DC. Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the kappa opioid agonist Salvinorin A in humans. Biol Psychiatry. 2012;72:871\u20139.","journal-title":"Biol Psychiatry"},{"key":"5227_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/BF00432213","volume":"86","author":"RF Mucha","year":"1985","unstructured":"Mucha RF, Herz A. Motivational properties of kappa and mu opioid receptor agonists studied with place and taste preference conditioning. Psychopharmacology. 1985;86:274\u201380.","journal-title":"Psychopharmacology"},{"key":"5227_CR4","first-page":"563","volume":"75","author":"TS Shippenberg","year":"1986","unstructured":"Shippenberg TS, Herz A. Differential effects of mu and kappa opioid systems on motivational processes. NIDA Res Monogr. 1986;75:563\u20136.","journal-title":"NIDA Res Monogr"},{"key":"5227_CR5","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/s41583-018-0028-x","volume":"19","author":"E Darcq","year":"2018","unstructured":"Darcq E, Kieffer BL. Opioid receptors: drivers to addiction? Nat Rev Neurosci. 2018;19:499\u2013514.","journal-title":"Nat Rev Neurosci"},{"key":"5227_CR6","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1038\/npp.2013.171","volume":"38","author":"VI Chefer","year":"2013","unstructured":"Chefer VI, Backman CM, Gigante ED, Shippenberg TS. Kappa opioid receptors on dopaminergic neurons are necessary for kappa-mediated place aversion. Neuropsychopharmacology. 2013;38:2623\u201331.","journal-title":"Neuropsychopharmacology."},{"key":"5227_CR7","doi-asserted-by":"publisher","first-page":"12917","DOI":"10.1523\/JNEUROSCI.2444-15.2015","volume":"35","author":"JM Ehrich","year":"2015","unstructured":"Ehrich JM, Messinger DI, Knakal CR, Kuhar JR, Schattauer SS, Bruchas MR, Zweifel LS, Kieffer BL, Phillips PE, Chavkin C. Kappa opioid receptor-induced aversion requires p38 MAPK activation in VTA dopamine neurons. J Neurosci. 2015;35:12917\u201331.","journal-title":"J Neurosci"},{"key":"5227_CR8","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1038\/s41386-018-0155-0","volume":"44","author":"JJ Liu","year":"2019","unstructured":"Liu JJ, Chiu YT, DiMattio KM, Chen C, Huang P, Gentile TA, Muschamp JW, Cowan A, Mann M, Liu-Chen LY. Phosphoproteomic approach for agonist-specific signaling in mouse brains: mTOR pathway is involved in kappa opioid aversion. Neuropsychopharmacology. 2019;44:939\u201349.","journal-title":"Neuropsychopharmacology"},{"key":"5227_CR9","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00213-003-1680-y","volume":"172","author":"MS Todtenkopf","year":"2004","unstructured":"Todtenkopf MS, Marcus JF, Portoghese PS, Carlezon WA Jr. Effects of kappa-opioid receptor ligands on intracranial self-stimulation in rats. Psychopharmacology. 2004;172:463\u201370.","journal-title":"Psychopharmacology"},{"key":"5227_CR10","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.biopsych.2013.07.042","volume":"76","author":"SE Russell","year":"2014","unstructured":"Russell SE, Rachlin AB, Smith KL, Muschamp J, Berry L, Zhao Z, Chartoff EH. Sex differences in sensitivity to the depressive-like effects of the kappa opioid receptor agonist U-50488 in rats. Biol Psychiatry. 2014;76:213\u201322.","journal-title":"Biol Psychiatry"},{"key":"5227_CR11","doi-asserted-by":"publisher","first-page":"ra117","DOI":"10.1126\/scisignal.aai8441","volume":"9","author":"TF Brust","year":"2016","unstructured":"Brust TF, Morgenweck J, Kim SA, Rose JH, Locke JL, Schmid CL, Zhou L, Stahl EL, Cameron MD, Scarry SM, et al. Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. Sci Signal. 2016;9:ra117.","journal-title":"Sci Signal"},{"key":"5227_CR12","first-page":"735","volume":"22","author":"S Page","year":"2019","unstructured":"Page S, Mavrikaki MM, Lintz T, Puttick D, Roberts E, Rosen H, Carroll FI, Carlezon WA, Chartoff EH. Behavioral pharmacology of novel kappa opioid receptor antagonists in rats. Int J Neuropsychopharmacol. 2019;22:735\u201345.","journal-title":"Int J Neuropsychopharmacol"},{"key":"5227_CR13","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1037\/pha0000287","volume":"28","author":"KE Faunce","year":"2020","unstructured":"Faunce KE, Banks ML. Effects of repeated kappa-opioid receptor agonist U-50488 treatment and subsequent termination on intracranial self-stimulation in male and female rats. Exp Clin Psychopharmacol. 2020;28:44\u201354.","journal-title":"Exp Clin Psychopharmacol."},{"key":"5227_CR14","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1038\/nprot.2007.441","volume":"2","author":"WA Carlezon Jr","year":"2007","unstructured":"Carlezon WA Jr, Chartoff EH. Intracranial self-stimulation (ICSS) in rodents to study the neurobiology of motivation. Nat Protoc. 2007;2:2987\u201395.","journal-title":"Nat Protoc"},{"key":"5227_CR15","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1124\/pr.112.007419","volume":"66","author":"SS Negus","year":"2014","unstructured":"Negus SS, Miller LL. Intracranial self-stimulation to evaluate abuse potential of drugs. Pharmacol Rev. 2014;66:869\u2013917.","journal-title":"Pharmacol Rev"},{"key":"5227_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1124\/jpet.114.216820","volume":"352","author":"KL White","year":"2015","unstructured":"White KL, Robinson JE, Zhu H, DiBerto JF, Polepally PR, Zjawiony JK, Nichols DE, Malanga CJ, Roth BL. The G protein-biased kappa-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo. J Pharmacol Exp Ther. 2015;352:98\u2013109.","journal-title":"J Pharmacol Exp Ther"},{"key":"5227_CR17","volume-title":"The mouse brain in stereotaxic coordinates","author":"KBJ Franklin","year":"1997","unstructured":"Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coordinates. San Diego: Academic Press; 1997."},{"key":"5227_CR18","doi-asserted-by":"publisher","first-page":"E1648","DOI":"10.1073\/pnas.1315542111","volume":"111","author":"JW Muschamp","year":"2014","unstructured":"Muschamp JW, Hollander JA, Thompson JL, Voren G, Hassinger LC, Onvani S, Kamenecka TM, Borgland SL, Kenny PJ, Carlezon WA Jr. Hypocretin (orexin) facilitates reward by attenuating the antireward effects of its cotransmitter dynorphin in ventral tegmental area. Proc Natl Acad Sci USA. 2014;111:E1648\u201355.","journal-title":"Proc Natl Acad Sci USA."},{"key":"5227_CR19","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/0031-9384(86)90388-4","volume":"37","author":"E Miliaressis","year":"1986","unstructured":"Miliaressis E, Rompre PP, Laviolette P, Philippe L, Coulombe D. The curve-shift paradigm in self-stimulation. Physiol Behav. 1986;37:85\u201391.","journal-title":"Physiol Behav"},{"key":"5227_CR20","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/0006-8993(89)91401-7","volume":"477","author":"PP Rompre","year":"1989","unstructured":"Rompre PP, Wise RA. Opioid-neuroleptic interaction in brainstem self-stimulation. Brain Res. 1989;477:144\u201351.","journal-title":"Brain Res"},{"key":"5227_CR21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1530-0277.2009.01069.x","volume":"34","author":"EW Fish","year":"2010","unstructured":"Fish EW, Riday TT, McGuigan MM, Faccidomo S, Hodge CW, Malanga CJ. Alcohol, cocaine, and brain stimulation-reward in C57Bl6\/J and DBA2\/J mice. Alcohol Clin Exp Res. 2010;34:81\u20139.","journal-title":"Alcohol Clin Exp Res"},{"key":"5227_CR22","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.bbr.2012.06.012","volume":"234","author":"JE Robinson","year":"2012","unstructured":"Robinson JE, Agoglia AE, Fish EW, Krouse MC, Malanga CJ. Mephedrone (4-methylmethcathinone) and intracranial self-stimulation in C57BL\/6\u00a0J mice: comparison to cocaine. Behav Brain Res. 2012;234:76\u201381.","journal-title":"Behav Brain Res"},{"key":"5227_CR23","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1007\/s00213-014-3600-8","volume":"231","author":"EW Fish","year":"2014","unstructured":"Fish EW, Whitman BJ, DiBerto JF, Robinson JE, Morrow AL, Malanga CJ. Effects of the neuroactive steroid allopregnanolone on intracranial self-stimulation in C57BL\/6\u00a0J mice. Psychopharmacology. 2014;231:3415\u201323.","journal-title":"Psychopharmacology"}],"container-title":["BMC Research Notes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-020-05227-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13104-020-05227-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13104-020-05227-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,13]],"date-time":"2021-08-13T19:11:41Z","timestamp":1628881901000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcresnotes.biomedcentral.com\/articles\/10.1186\/s13104-020-05227-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,14]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["5227"],"URL":"https:\/\/doi.org\/10.1186\/s13104-020-05227-7","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-29716\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-29716\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-29716\/v2","asserted-by":"object"}]},"ISSN":["1756-0500"],"issn-type":[{"value":"1756-0500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,14]]},"assertion":[{"value":"18 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All experiments were conducted in accordance with the National Institutes of Health guidelines for the Care and Use of Laboratory Animals and with approval from Temple University School of Medicine Institutional Animal Care and Use Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"384"}}